CENTESSA PHARMACEUTICALS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Centessa Pharmaceuticals plc - CNTAPRNewsWire • 10/08/22
INVESTOR ALERT: Investors in Centessa Pharmaceuticals plc With Substantial Losses Have Opportunity to Lead Class Action Lawsuit - CNTANewsfile Corp • 10/04/22
INVESTOR NOTICE: Centessa Pharmaceuticals plc Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – CNTABusiness Wire • 10/03/22
INVESTOR ALERT: Centessa Pharmaceuticals plc Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - CNTAPRNewsWire • 10/01/22
CENTESSA PHARMACEUTICALS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Centessa Pharmaceuticals plc - CNTABusiness Wire • 10/01/22
Centessa Pharmaceuticals plc Shareholder Update: Robbins LLP Reminds Investors of Class Action Against Centessa Pharmaceuticals plc (CNTA)Business Wire • 09/30/22
CENTESSA PHARMACEUTICALS PLC (CNTA) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Centessa Pharmaceuticals plc (CNTA)Newsfile Corp • 09/30/22
CENTESSA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Centessa Pharmaceuticals Plc and Encourages Investors to Contact the FirmBusiness Wire • 09/30/22
INVESTOR ALERT: Centessa Pharmaceuticals plc Investors with Substantial Losses Have Opportunity to Lead the Centessa Class Action Lawsuit - CNTABusiness Wire • 09/29/22
Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Centessa Pharmaceuticals plc (CNTA)Business Wire • 09/29/22
SHAREHOLDER ALERT: Holzer & Holzer Announces a Class Action Was Filed on Behalf of Centessa (CNTA) Investors and Encourages Investors With Significant Losses to Contact the FirmNewsfile Corp • 09/29/22
Centessa Pharmaceuticals Announces Poster Presentation Featuring Novel Orexin Receptor 2 (OX2R) Agonist Discovery Pipeline at the 26th Conference of the European Sleep Research Society (Sleep Europe 2022)GlobeNewsWire • 09/20/22
Centessa Pharmaceuticals Announces Non-Human Primate Pharmacokinetic and Safety Data for LB101 (PD-L1xCD47) Demonstrating Potential for Enhanced Therapeutic IndexGlobeNewsWire • 09/12/22
ROSEN, A LEADING LAW FIRM, Encourages Centessa Pharmaceuticals plc Investors to Inquire About Securities Class Action Investigation - CNTANewsfile Corp • 09/05/22
GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Centessa Pharmaceuticals plc Investors to Inquire About Class Action Investigation - CNTANewsfile Corp • 08/26/22
CNTA INVESTOR NOTICE: ROSEN, A TOP RANKED LAW FIRM, Encourages Centessa Pharmaceuticals plc Investors with Losses to Inquire About Class Action Investigation - CNTAPRNewsWire • 08/25/22
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Centessa Pharmaceuticals plc with Losses of $100,000 to Contact the FirmNewsfile Corp • 08/17/22
ONGOING INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Centessa Pharmaceuticals plc with Losses of $100,000 to Contact the FirmNewsfile Corp • 08/16/22
ONGOING INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Centessa Pharmaceuticals plc with Losses of $100,000 to Contact the FirmNewsfile Corp • 08/15/22
INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Centessa Pharmaceuticals plc with Losses of $100,000 to Contact the FirmBusiness Wire • 08/15/22
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Centessa Pharmaceuticals plcNewsfile Corp • 08/13/22
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Centessa Pharmaceuticals plc with Losses of $100,000 to Contact the FirmBusiness Wire • 08/12/22
EQUITY ALERT: Rosen Law Firm Encourages Centessa Pharmaceuticals plc Investors with Losses in Excess of $100K to Inquire About Class Action Investigation – CNTABusiness Wire • 08/12/22
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2022; Provides Program Update for ZF874GlobeNewsWire • 08/10/22
Centessa Pharmaceuticals Announces Addition of Harris L. Rotman, PhD, as Senior Vice President of Regulatory AffairsGlobeNewsWire • 07/25/22
